Q-omics provides the consensus-scored RIN1 profile across patient tissues and cancer cell-line models. RIN1 expression is associated with patient survival in 27 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, RIN1 is differentially expressed in 15, with the highest sampling consensus in THCA. Additionally, RIN1 RNA expression shows 18,340 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight KIRC, THCA, and TGCT as cancer lineages where RIN1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RIN1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RIN1 survival associations across molecular data types. RIN1 RNA expression shows survival associations in the most cancer types (27), followed by mutation status (6) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RIN1 RNA expression–survival associations across cancer types. High RIN1 expression shows unfavorable associations in KIRC, MESO, LGG, LUAD and LIHC, but favorable associations in READ. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for RIN1 RNA expression.
This table summarizes RIN1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15, while mass-spec protein shows differences in 7. The strongest signals are observed in THCA for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for RIN1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RIN1 shows higher tumor expression in THCA, COAD, KIRC, KIRP, HNSC and LIHC. The THCA box plot shows higher RIN1 RNA expression in tumor versus normal tissue (log2 FC = +1.845, t-test p < 0.001).
This table shows molecular features associated with RIN1 in patient tissues and cancer cell lines. In patient samples, RIN1 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, RIN1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BREAST, while CRISPR and shRNA rows add functional-dependency signals in BONE and BLOOD_Leukemia.
